Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting learning session on first line management of ALK positive lung cancer.
In this webinar, a panel discussion would take place involving Dr. Jessicca Lin as the primary speaker and Dr. T. Raja, Dr. Amit Rauthan, Dr. B. K. Smruti and many other panelists who will share the important facts associated with first line management of ALK positive lung cancer.
Starting with the case scenario of non-small cell lung cancer, Dr Jessica has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, the panel discussion will give more knowledge.
ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.
Therefore, you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
FDA-approved FGFR inhibitors show promise against rare and aggressive pediatric brain tumor
2.
Sickle Cell Disease Drug Pulled From Global Markets
3.
A US health panel advises starting mammograms at age 40 rather than 50.
4.
'Converging' Evidence of Link Between Air Pollution and Breast Cancer
5.
Getting More Done With Less Blood.
1.
Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice
2.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
3.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
4.
Unlocking the Potential of Palbociclib: A Comprehensive Overview
5.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
3.
Current Scenario of Cancer- The Incidence of Cancer in Men
4.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation